118 related articles for article (PubMed ID: 25845968)
21. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
22. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
23. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
24. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
26. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Iwata TN; Sugihara K; Wada T; Agatsuma T
PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model.
Li F; Guo Z; Yu H; Zhang X; Si T; Liu C; Yang X; Qi L
Neoplasma; 2014; 61(6):659-71. PubMed ID: 25341995
[TBL] [Abstract][Full Text] [Related]
30. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.
Pico de Coaña Y; Masucci G; Hansson J; Kiessling R
Cancer Immunol Immunother; 2014 Sep; 63(9):977-83. PubMed ID: 24966003
[TBL] [Abstract][Full Text] [Related]
33. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
35. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
36. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
[TBL] [Abstract][Full Text] [Related]
37. IFN-γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment.
Guo Q; Lv Z; Fu Q; Jiang C; Liu Y; Lai L; Chen Q; Shen J; Wang Q
Int Immunopharmacol; 2012 Feb; 12(2):425-32. PubMed ID: 22226750
[TBL] [Abstract][Full Text] [Related]
38. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L; Amoozgar Z; Huang J; Saleh MH; Xing D; Orsulic S; Goldberg MS
Cancer Immunol Res; 2015 Sep; 3(9):1030-41. PubMed ID: 26056145
[TBL] [Abstract][Full Text] [Related]
39. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses.
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Nabi Afjadi M; Ghani S; Aghaei Vanda N; Ghaderi Sede MJ; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):10068-10080. PubMed ID: 32488862
[TBL] [Abstract][Full Text] [Related]
40. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]